Co-flumactone (Hydroflumethiazide and spironolactone )
Co-tenidone (Atenolol and Chlortalidone)
Co-triamterzide (Triamterene and hydrochlorothiazide)
For patients with Long QT syndrome. Licensed product discontinued April 2016.
Oxprenolol Hydrochloride and Cyclopenthiazide (Trasidrex®)
Pindolol and Clopamide (Viskaldix®)
Spironolactone and furosemide (Lasilactone®)
Timolol Maleate and Bendroflumethiazide (Prestim®)
Timolol Maleate and Co-amilozide (Moducren®)
Triamterene and chlortalidone (Kalspare®)
Triamterene and furosemide (Frusene®)
Triamterene and hydrochlorothiazide (Dyazide®)
Section Title (top level)
Section Title (sub level)
First Choice item
Non Formulary section
Display tracking information
Link to adult BNF
Link to children's BNF
Link to SPCs
Scottish Medicines Consortium
High Cost Medicine
Cancer Drugs Fund
Traffic Light Status Information
Red: Medicines which should only be prescribed in secondary care by a specialist.
Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred.
Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO).
Green: Medicines which are suitable for initiation and ongoing prescribing within primary care.
Brown: Medicines which should only be prescribed in restricted circumstances.
Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety.